Ben Tran, MD Peter MacCallum Cancer Centre, Melbourne, Australia gives an update on the date from the PROfound trial (NCT02987543). Last year the PROfound trial met its primary endpoint of progression-free survival (PFS) with olaparib vs enzalutamide or abiraterone. This year, the overall survival (OS) data were presented for olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC), BRCA1, BRCA2, and ATM mutations. Dr Tran also discusses the data from the IPATential 150 study (NCT03072238) which investigates the use of ipatasertib plus abiraterone and prednisone compared with placebo plus abiraterone and prednisone in patients with (mCRPC). Furthermore, Dr Tran discusses the data from the KEYNOTE-361 trial (NCT02853305), the DANUBE trial (NCT02516241), and the CheckMate 9ER trial (NCT03141177). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).